REGENERON PHARMACEUTICALS INC 4

Accession 0001237899-15-000049

$REGNCIK 0000872589operating

View on SEC.gov Company Profile

Filed

Aug 16, 8:00 PM ET

Accepted

Aug 17, 4:01 PM ET

Size

53.9 KB

Accession

0001237899-15-000049

Insider Transaction Report

Form 4

Period: 2015-08-13

REGENERON PHARMACEUTICALS INCREGN

Powchik Peter

SVP Clinical Development

Transactions

Exercise/Conversion
Common Stock
2015-08-13$179.13/sh+14,625$2,619,776→ 33,030 total
Tax Payment
Common Stock
2015-08-13$579.35/sh−3,755$2,175,459→ 36,966 total
Exercise/Conversion
Common Stock
2015-08-13$30.63/sh+4,736$145,064→ 41,702 total
Tax Payment
Common Stock
2015-08-13$579.35/sh−250$144,838→ 41,452 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2015-08-13−8,000→ 6,079 total
Exercise: $52.03Exp: 2021-12-16→ Common Stock (8,000 underlying)
Sale
Common Stock
2015-08-14$570.63/sh−3,603$2,055,980→ 34,298 total
Tax Payment
Common Stock
2015-08-13$579.35/sh−2,146$1,243,285→ 39,306 total
Sale
Common Stock
2015-08-14$577.75/sh−2,258$1,304,560→ 17,321 total
Exercise/Conversion
Common Stock
2015-08-13$52.03/sh+8,000$416,240→ 41,439 total
Sale
Common Stock
2015-08-14$572.60/sh−2,800$1,603,280→ 25,900 total
Sale
Common Stock
2015-08-14$574.75/sh−900$517,275→ 22,283 total
Exercise/Conversion
Common Stock
2015-08-13$270.43/sh+10,000$2,704,300→ 25,821 total
Tax Payment
Common Stock
2015-08-13$579.35/sh−2,749$1,592,633→ 18,405 total
Tax Payment
Common Stock
2015-08-13$579.35/sh−10,795$6,254,083→ 33,439 total
Tax Payment
Common Stock
2015-08-13$579.35/sh−718$415,973→ 40,721 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2015-08-13−23,000→ 14,079 total
Exercise: $52.03Exp: 2021-12-16→ Common Stock (23,000 underlying)
Tax Payment
Common Stock
2015-08-13$579.35/sh−4,521$2,619,241→ 28,509 total
Tax Payment
Common Stock
2015-08-13$579.35/sh−5,210$3,018,414→ 23,299 total
Tax Payment
Common Stock
2015-08-13$579.35/sh−2,065$1,196,358→ 44,234 total
Sale
Common Stock
2015-08-14$571.54/sh−5,598$3,199,481→ 28,700 total
Sale
Common Stock
2015-08-14$573.64/sh−2,717$1,558,580→ 23,183 total
Sale
Common Stock
2015-08-14$576.65/sh−2,004$1,155,607→ 19,579 total
Sale
Common Stock
2015-08-14$578.63/sh−1,500$867,945→ 15,821 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2015-08-13−10,000→ 30,000 total
Exercise: $270.43Exp: 2023-12-13→ Common Stock (10,000 underlying)
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2015-08-13−14,625→ 29,250 total
Exercise: $179.13Exp: 2022-12-14→ Common Stock (14,625 underlying)
Tax Payment
Common Stock
2015-08-13$579.35/sh−4,667$2,703,826→ 21,154 total
Exercise/Conversion
Common Stock
2015-08-13$52.03/sh+23,000$1,196,690→ 46,299 total
Sale
Common Stock
2015-08-14$569.63/sh−1,405$800,330→ 37,901 total
Sale
Common Stock
2015-08-14$575.47/sh−700$402,829→ 21,583 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2015-08-13−4,736→ 0 total
Exercise: $30.63Exp: 2020-12-14→ Common Stock (4,736 underlying)

Holdings

Common Stock
(indirect: by GRAT)
12,890
Common Stock
(indirect: By 401(k))
1,652

Footnotes (13)

[F1]Represents volume-weighted average price of sales of 1,405 shares of Company stock on August 14, 2015 at prices ranging from $569.11 to $570.09. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
[F10]Represents volume-weighted average price of sales of 1,500 shares of Company stock on August 14, 2015 at prices ranging from $578.14 to $579.07. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
[F11]The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
[F12]The option became exercisable with respect to all shares underlying the option on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014.
[F13]The stock option award vests in four equal annual installments, commencing one year after the date of grant.
[F2]Represents volume-weighted average price of sales of 3,603 shares of Company stock on August 14, 2015 at prices ranging from $570.15 to $571.09. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
[F3]Represents volume-weighted average price of sales of 5,598 shares of Company stock on August 14, 2015 at prices ranging from $571.14 to $572.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
[F4]Represents volume-weighted average price of sales of 2,800 shares of Company stock on August 14, 2015 at prices ranging from $572.23 to $573.06. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
[F5]Represents volume-weighted average price of sales of 2,717 shares of Company stock on August 14, 2015 at prices ranging from $573.15 to $574.09. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
[F6]Represents volume-weighted average price of sales of 900 shares of Company stock on August 14, 2015 at prices ranging from $574.20 to $575.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
[F7]Represents volume-weighted average price of sales of 700 shares of Company stock on August 14, 2015 at prices ranging from $575.30 to $576.04. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
[F8]Represents volume-weighted average price of sales of 2,004 shares of Company stock on August 14, 2015 at prices ranging from $576.16 to $577.09. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.
[F9]Represents volume-weighted average price of sales of 2,258 shares of Company stock on August 14, 2015 at prices ranging from $577.24 to $578.08. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 14, 2015 at each separate price.

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT

Issuer

REGENERON PHARMACEUTICALS INC

CIK 0000872589

→

Entity typeoperating

IncorporatedNY

Related Parties

filerCIK 0000872589

Filing Metadata

Form type: 4
Filed: Aug 16, 8:00 PM ET
Accepted: Aug 17, 4:01 PM ET
Size: 53.9 KB

View on SEC.gov